ALX 40-4C Trifluoroacetate

Name: ALX 40-4C Trifluoroacetate
Brand: MedChemExpress
SKU: HY-P7061A
Rating: 4.5 (1 reviews)

Cat. No.: HY-P7061A Purity: 96.65%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC₅₀ of 2.9 μM.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

ALX 40-4C Trifluoroacetate Chemical Structure

Size	Price	Stock	Quantity
1 mg	USD 240	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 850	In-stock	Estimated Time of Arrival: December 31
10 mg		Get quote
50 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of ALX 40-4C Trifluoroacetate:

ALX 40-4C acetate Get quote
ALX 40-4C Get quote

1 Publications Citing Use of MCE ALX 40-4C Trifluoroacetate

•Exp Cell Res. 2019 May 15;378(2):131-138. [Abstract]

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All CXCR Isoform Specific Products:

View All Isoforms

CXCR CXCR1 CXCR2 CXCR3 CXCR4 CXCR7 CXCR6

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[3]

SDF-1-CXCR4

1 μM (Ki)

APJ receptor

2.9 μM (IC₅₀)

In Vitro

ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the chemokine receptor CXCR4, interacts with the second extracellular loop of CXCR4 and inhibits infection exclusively by blocking direct virus-CXCR4 interactions^[1]. ALX 40-4C shows potent anti HIV-1 effect, with EC₅₀s of 0.34 ± 0.04 μg/mL, 0.37 ± 0.01 μg/mL for HIV-1 NL4-3, NC10, and 0.18 ± 0.11 μg/mL, 0.06 ± 0.02 μg/mL for HIV-1 HXB2, HC43, respectively, and with a CC₅₀ (50% cytotoxic concentration) of 21 μg/mL. ALX 40-4C also exhibits potent activity against env-recombinant HIV, with EC₅₀s of 0.38 ± 0.01 μg/mL, 0.40 ± 0.0 μg/mL for HIV-1 NL4-3 env, NC10, and 1.34 ± 0.06 μg/mL, 1.02 ± 0.29 μg/mL for HIV-1 HXB2 env, HC43, and a CC₅₀ of 21 μg/mL^[2]. ALX 40-4C binds to APJ with an IC₅₀ of 2.9 μM. ALX 40-4C inhibits HIV-1 gp120/APJ-mediated cell membrane fusion, with an IC₅₀s of 3.41 μM and 3.1 μM for IIIB isolate and 89.6 isolate, respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

1464.74 (free base)

Formula

C₅₆H₁₁₃N₃₇O₁₀.xC₂HF₃O₂

Appearance

Solid

Color

White to off-white

Sequence

Ac-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-NH2

Sequence Shortening

Ac-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-NH2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 50 mg/mL (Need ultrasonic)

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 96.65%

Select Batch:

Data Sheet (284 KB) SDS (252 KB)

COA (261 KB) RP-HPLC (214 KB) Elemental Analysis Report (120 KB)

Handling Instructions (2659 KB)

References

[1]. Doranz BJ, et al. Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res Hum Retroviruses. 2001 Apr 10;17(6):475-86. [Content Brief]

[2]. Armand-Ugón M, et al. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antiviral Res. 2003 Jul;59(2):137-42. [Content Brief]

[3]. Zhou N, et al. Binding of ALX40-4C to APJ, a CNS-based receptor, inhibits its utilization as a co-receptor by HIV-1. Virology. 2003 Jul 20;312(1):196-203. [Content Brief]

Kinase Assay
^[3]

The stably transfected cells are harvested in PBS (Ca²⁺ and Mg²⁺ free) plus 0.5 nM EDTA and washed twice with PBS. Ligand binding experiments are performed using a single concentration (0.2 nM) of ¹²⁵I-Apelin-13 in the absence or presence of increasing concentrations of unlabeled Apelin-13 or ALX 40-4C in a final volume of 100 μL of binding buffer (50 nM Hepes, pH 7.4, 1 nM CaCl₂, 5 nM MgCl₂, 0.1% bovine serum albumin) containing 5 × 10⁵ cells. Nonspecific binding is determined by the addition of 1 μM unlabeled Apelin-13. Samples are incubated for 90 min at room temperature. The incubation is terminated by separating the cells from the binding buffer by centrifugation and washing once with 500 μL of cold binding buffer. Bound ligands are determined by counting gamma emissions. At least three independent experiments are performed^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Doranz BJ, et al. Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res Hum Retroviruses. 2001 Apr 10;17(6):475-86. [Content Brief]

[2]. Armand-Ugón M, et al. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antiviral Res. 2003 Jul;59(2):137-42. [Content Brief]

[3]. Zhou N, et al. Binding of ALX40-4C to APJ, a CNS-based receptor, inhibits its utilization as a co-receptor by HIV-1. Virology. 2003 Jul 20;312(1):196-203. [Content Brief]